Characteristics of SR and HR patients
| . | SR patients n (%) . | HR patients n (%) . | P value . |
|---|---|---|---|
| Number of evaluable patients | 99 (100) | 383 (100) | |
| Gender | |||
| Male | 59 (60) | 203 (53) | .6 |
| Female | 40 (40) | 180 (47) | .6 |
| Age | |||
| <1 y | 2 (2) | 61 (16) | .01 |
| 1-2 y | 7 (7) | 45 (12) | .1 |
| 2-10 y | 43 (43) | 138 (36) | .5 |
| >10 y | 47 (47) | 139 (36) | .3 |
| WBC count (×109/L) | |||
| <10 | 31 (31) | 140 (36) | .6 |
| 10-99 | 57 (58) | 179 (47) | .3 |
| >100 | 11 (11) | 64 (17) | .3 |
| CNS leukemia (yes) | 4 (4) | 36 (9) | .2 |
| FAB subtype | |||
| M0 | 0 (0) | 34 (9) | <.01 |
| M1 | 5 (5) | 83 (22) | .02 |
| M2 | 60 (61) | 31 (8) | <.01 |
| M4 | 10 (10) | 30 (8) | .8 |
| M4 Eo | 17 (17) | 26 (7) | .08 |
| M5 | 2 (2) | 115 (30) | <.01 |
| M6 | 0 (0) | 5 (1) | 1.0 |
| M7 | 0 (0) | 44 (11) | <.01 |
| Unclassifiable/not known | 5 (5) | 15 (4) | 1.0 |
| FLT3 aberrations | |||
| Patients tested for FLT3 aberrations | 73 | 311 | |
| ITD | 0 (0) | 42 (13) | <.01 |
| ALM (D835/I836) | 2 (3) | 8 (3) | 1.0 |
| Wild-type | 71 (96) | 261 (84) | .5 |
| Other molecular aberrations | |||
| Patients tested | 59 | 185 | |
| NPM mutations | 0 (0) | 14 (8) | <.01 |
| CEBPα mutations | 0 (0) | 18 (10) | <.01 |
| Outcome | |||
| Dead during induction | 3 (3) | 10 (3) | 1.0 |
| Dead in CR after induction | 4 (4) | 33 (7) | .5 |
| Relapsed | 24 (24) | 79 (21) | .7 |
| Salvaged after relapse | 17 (17) | 13 (3) | <.01 |
| Dead during/after salvage therapy | 3 (3) | 16 (4) | 1 |
| Dead after relapse | 4 (4) | 50 (13) | .04 |
| . | SR patients n (%) . | HR patients n (%) . | P value . |
|---|---|---|---|
| Number of evaluable patients | 99 (100) | 383 (100) | |
| Gender | |||
| Male | 59 (60) | 203 (53) | .6 |
| Female | 40 (40) | 180 (47) | .6 |
| Age | |||
| <1 y | 2 (2) | 61 (16) | .01 |
| 1-2 y | 7 (7) | 45 (12) | .1 |
| 2-10 y | 43 (43) | 138 (36) | .5 |
| >10 y | 47 (47) | 139 (36) | .3 |
| WBC count (×109/L) | |||
| <10 | 31 (31) | 140 (36) | .6 |
| 10-99 | 57 (58) | 179 (47) | .3 |
| >100 | 11 (11) | 64 (17) | .3 |
| CNS leukemia (yes) | 4 (4) | 36 (9) | .2 |
| FAB subtype | |||
| M0 | 0 (0) | 34 (9) | <.01 |
| M1 | 5 (5) | 83 (22) | .02 |
| M2 | 60 (61) | 31 (8) | <.01 |
| M4 | 10 (10) | 30 (8) | .8 |
| M4 Eo | 17 (17) | 26 (7) | .08 |
| M5 | 2 (2) | 115 (30) | <.01 |
| M6 | 0 (0) | 5 (1) | 1.0 |
| M7 | 0 (0) | 44 (11) | <.01 |
| Unclassifiable/not known | 5 (5) | 15 (4) | 1.0 |
| FLT3 aberrations | |||
| Patients tested for FLT3 aberrations | 73 | 311 | |
| ITD | 0 (0) | 42 (13) | <.01 |
| ALM (D835/I836) | 2 (3) | 8 (3) | 1.0 |
| Wild-type | 71 (96) | 261 (84) | .5 |
| Other molecular aberrations | |||
| Patients tested | 59 | 185 | |
| NPM mutations | 0 (0) | 14 (8) | <.01 |
| CEBPα mutations | 0 (0) | 18 (10) | <.01 |
| Outcome | |||
| Dead during induction | 3 (3) | 10 (3) | 1.0 |
| Dead in CR after induction | 4 (4) | 33 (7) | .5 |
| Relapsed | 24 (24) | 79 (21) | .7 |
| Salvaged after relapse | 17 (17) | 13 (3) | <.01 |
| Dead during/after salvage therapy | 3 (3) | 16 (4) | 1 |
| Dead after relapse | 4 (4) | 50 (13) | .04 |
ALM, activating loop mutations; CEBPα, CCAAT/enhancer binding protein; ITD, internal tandem duplication; NPM, nucleophosmin; Boldface P values denote statistically significant differences (<.05).